ClinicalTrials.gg
RecruitingNCT07073950ORATOSUpdated Sep 18, 2026

A Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation

A Phase 4 interventional study of Budesonide/Glycopyrronium/Formoterol Fumarate and Placebo in Chronic Obstructive Pulmonary Disease and Hyperinflation, sponsored by AstraZeneca. Recruiting at 7 sites in 2 countries. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-09-18.

Sponsored by AstraZeneca · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Started Nov 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 43 studies testing budesonide in Pulmonary Disease, Chronic Obstructive — 3 open to participants now, 3 under way, 1 of them phase 3. Budesonide · Pulmonary Disease, Chronic Obstructive.

Planned enrollment
27th of 43
56 · median 99
Started
2025
with 2 others
Phase 4
18 of 43
2 open now
Registered
43rd of 43
by date
Lead sponsor
10 of 43
AstraZeneca

Among the 43 studies testing budesonide in Pulmonary Disease, Chronic Obstructive, this one is the 27th largest by planned enrollment, is one of 3 that started in 2025, is one of 18 in phase 4, and was the 43rd registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

3 of the 43 studies testing budesonide in Pulmonary Disease, Chronic Obstructive are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About budesonide

Budesonide: first FDA approval 1994 (RHINOCORT), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing budesonide in Pulmonary Disease, Chronic Obstructive, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate the effect of BGF MDI compared with placebo MDI on cardiac and lung function when administered in participants diagnosed with COPD and hyperinflation.

Read the detailed description

This is a Phase IV, randomised, double blind, multiple centre, placebo controlled, crossover study where the effectiveness of BGF MDI in comparison with matching placebo MDI on cardiac and lung function will be evaluated in patients with COPD and hyperinflation.

The study will comprise of:

  • Screening period
  • Participants will receive placebo inhaler and salbutamol before randomization
  • Two treatment periods of 21 days each, where participants will be randomized 1:1 to receive either the study intervention BGF metered-dose inhaler (MDI) or placebo in Period 1 then crossover to matching placebo or BGF in Period 2
  • A final follow-up period
03

Conditions studied

  • Chronic Obstructive Pulmonary Disease
  • Hyperinflation

Keywords

  • Metered Dose Inhalers (MDI)
  • Inhaled Corticosteroid (ICS)
  • Long-acting muscarinic antagonist (LAMA)
  • Long-acting beta2 agonist (LABA)
04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Current or former smoker with a history of ≥ 10 pack-years of tobacco smoking.
  • A diagnosis of confirmed by a post-bronchodilator /forced vital capacity (FEV1/FVC) \< 0.7.
  • At Visit 1: A pre-bronchodilator FEV1 \< 80%.
  • At Visit 1: Peripheral blood eosinophil count \< 300 cells/cubic millimeter (mm³), with no recorded history of eosinophil count > 300 cells/mm³ in the past 12 months.
  • At Visit 1: Modified Medical Research Council (mMRC) ≥ 1.
  • At Visit 2: A pre-bronchodilator functional residual capacity (FRC) of > 135% of predicted normal FRC.
  • At Visit 2: A post-bronchodilator FEV1 ≥ 30% and \< 80% of the predicted normal value.
  • Participants must be on mono-, dual-, or triple-inhaled maintenance COPD treatment.
  • Female participants must either be not of or using a form of highly effective .
  • All women of child bearing potential must have a negative pregnancy test at the Visit 1.

Exclusion Criteria:

  • A current diagnosis of asthma, asthma-COPD overlap, or any other chronic respiratory disease other than COPD, such as alpha-1 antitrypsin deficiency, active tuberculosis, lung cancer, lung fibrosis, sarcoidosis, interstitial lung disease, and pulmonary hypertension.
  • History of a COPD exacerbation that required hospitalisation, or 2 or more COPD exacerbations that required systemic .
  • History of myocardial infarction or acute coronary syndrome.
  • History or current atrial or ventricular arrhythmia to be confirmed by (ECG).
  • Participants with a cardiac implantable electronic device, including pacemaker, implantable cardioverter defibrillator, or cardiac resynchronization therapy.
  • Participants with ECG interval at Visit 1 > 460 milliseconds (ms) for males and > 480 ms for females.
  • Participants who have had a respiratory tract infection within 8 weeks prior to Visit 1 and/or during the screening/run-in period.
  • Participants with lung lobectomy, lung volume reduction (during the study and within 3 months of Visit 1), or lung transplantation.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
56 participants (estimated)

Study arms

  • Experimental
    Sequence 1: BGF MDI and Placebo

    Participants will receive BGF MDI in Period 1 followed by Placebo in Period 2.

    Drug: Budesonide/Glycopyrronium/Formoterol Fumarate · Drug: Placebo · Device: Metered dose inhaler

  • Experimental
    Sequence 2: Placebo and BGF MDI

    Participants will receive Placebo in Period 1 followed by BGF MDI in Period 2.

    Drug: Budesonide/Glycopyrronium/Formoterol Fumarate · Drug: Placebo · Device: Metered dose inhaler

Interventions

  • DrugBudesonide/Glycopyrronium/Formoterol Fumarate

    Drug pages: Budesonide · Glycopyrrolate · Formoterol

    BGF will be administered as 2 inhalations via oral route of administration

  • DrugPlacebo

    Matching placebo will be administered as 2 inhalations via oral route of administration

  • DeviceMetered dose inhaler

    Participants will receive BGF and matching placebo via metered dose inhaler in treatment periods of the study.

06

What researchers measure

Primary outcomes

  1. Change from baseline in left ventricular end diastolic volume indexed by body surface area (LVEDVi) measured by magnetic resonance imaging (MRI)

    The effect of BGF relative to placebo on LVEDVi in participants with COPD and hyperinflation will be evaluated.

    Time frame: Up to 3 weeks

Secondary outcomes

  1. Change from baseline in functional residual capacity/total lung capacity (FRC/TLC) measured by body plethysmography

    The effect of BGF relative to placebo on FRC/TLC will be evaluated.

    Time frame: Up to 3 weeks

  2. Change from baseline in residual volume/total lung capacity (RV/TLC) measured by body plethysmography

    The effect of BGF relative to placebo on RV/TLC will be evaluated.

    Time frame: Up to 3 weeks

07

Study locations

6 of 7 sites recruiting
  • Research Site
    Ahrensburg, 22926, Germany
    Recruiting
  • Research Site
    Berlin, 14050, Germany
    Recruiting
  • Research Site
    Frankfurt, 60596, Germany
    Recruiting
  • Research Site
    Hanover, 30625, Germany
    Recruiting
  • Research Site
    Harefield, UB9 6JH, United Kingdom
    Withdrawn

    Not enrolling at this site.

  • Research Site
    London, W1T 6AH, United Kingdom
    Recruiting
  • Research Site
    Manchester, M23 9QZ, United Kingdom
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please refer to our disclosure commitment at: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secureresearchenvironmentVivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for May 2027, 18 months after the start.

Of 71 industry-sponsored phase 4 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 22. This study's planned 18 months is above that.

Counting every sponsor, half of 157 studies reached it within 19 months; a quarter within 12 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2025
First posted
Jul 20, 2025
StartActual
Nov 24, 2025
Primary completionEst.
May 31, 2027
CompletionEst.
May 31, 2027
Last update
Sep 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07073950
Lead sponsor
AstraZeneca
Collaborators
Parexel
Responsible party
Sponsor
First posted
Jul 20, 2025
Start date
Nov 24, 2025
Primary completion
May 31, 2027 (estimated)
Completion
May 31, 2027 (estimated)
Last update
Sep 18, 2026

Study contacts

AstraZeneca Clinical Study Information Center
Contact
information.center@astrazeneca.com
1-877-240-9479

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Budesonide · Glycopyrrolate · Formoterol

Start the discussion